-$0.35 Earnings Per Share Expected for Kodiak Sciences Inc. (NYSE:KOD) This Quarter

Equities analysts predict that Kodiak Sciences Inc. (NYSE:KOD) will post earnings per share (EPS) of ($0.35) for the current quarter, according to Zacks. Zero analysts have issued estimates for Kodiak Sciences’ earnings, with the lowest EPS estimate coming in at ($0.44) and the highest estimate coming in at ($0.29). Kodiak Sciences posted earnings per share of ($0.25) during the same quarter last year, which indicates a negative year over year growth rate of 40%. The firm is expected to announce its next quarterly earnings report on Thursday, March 26th.

According to Zacks, analysts expect that Kodiak Sciences will report full year earnings of ($1.20) per share for the current financial year, with EPS estimates ranging from ($1.30) to ($1.13). For the next financial year, analysts expect that the business will post earnings of ($3.51) per share, with EPS estimates ranging from ($6.04) to ($1.97). Zacks Investment Research’s EPS averages are a mean average based on a survey of analysts that that provide coverage for Kodiak Sciences.

KOD has been the topic of a number of recent analyst reports. JPMorgan Chase & Co. began coverage on shares of Kodiak Sciences in a report on Tuesday, December 24th. They set an “overweight” rating and a $82.00 price target on the stock. SunTrust Banks began coverage on Kodiak Sciences in a research report on Wednesday, February 5th. They issued a “buy” rating and a $101.00 price objective on the stock. Chardan Capital reaffirmed a “buy” rating on shares of Kodiak Sciences in a research report on Thursday, January 23rd. Roth Capital began coverage on Kodiak Sciences in a research note on Wednesday, January 8th. They set a “buy” rating and a $115.00 target price on the stock. Finally, Jefferies Financial Group initiated coverage on Kodiak Sciences in a research note on Friday, January 3rd. They issued a “buy” rating and a $100.00 price target for the company. Two research analysts have rated the stock with a hold rating and seven have issued a buy rating to the company’s stock. The stock presently has an average rating of “Buy” and an average price target of $84.78.

Kodiak Sciences stock traded up $4.78 during trading hours on Friday, hitting $62.39. The stock had a trading volume of 540,450 shares, compared to its average volume of 369,767. The stock’s 50-day moving average price is $64.15 and its 200-day moving average price is $38.24. Kodiak Sciences has a 12-month low of $5.86 and a 12-month high of $82.75.

In related news, Director Bros. Advisors Lp Baker bought 71,123 shares of the company’s stock in a transaction that occurred on Monday, February 24th. The shares were bought at an average price of $57.56 per share, for a total transaction of $4,093,839.88. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this hyperlink. In the last 90 days, insiders have purchased 2,073,296 shares of company stock worth $132,525,933.

Institutional investors have recently bought and sold shares of the stock. Marshall Wace LLP purchased a new position in Kodiak Sciences in the first quarter worth about $258,000. Marshall Wace North America L.P. purchased a new stake in shares of Kodiak Sciences during the 1st quarter valued at about $73,000. Vanguard Group Inc. lifted its stake in shares of Kodiak Sciences by 98.3% in the 2nd quarter. Vanguard Group Inc. now owns 763,472 shares of the company’s stock worth $8,932,000 after purchasing an additional 378,544 shares during the period. Morgan Stanley lifted its stake in shares of Kodiak Sciences by 88.6% in the 2nd quarter. Morgan Stanley now owns 21,027 shares of the company’s stock worth $246,000 after purchasing an additional 9,878 shares during the period. Finally, Rhumbline Advisers boosted its holdings in shares of Kodiak Sciences by 3.8% in the third quarter. Rhumbline Advisers now owns 23,543 shares of the company’s stock worth $339,000 after buying an additional 866 shares during the last quarter.

About Kodiak Sciences

Kodiak Sciences Inc, a clinical stage biopharmaceutical company, provides novel therapeutics to treat ophthalmic diseases. The company's lead product candidate is KSI-301, a vascular endothelial growth factor (VEGF)-biologic that is in Phase I clinical study to treat wet age-related macular degeneration (AMD) and diabetic retinopathy.

Read More: What is a Call Option?

Get a free copy of the Zacks research report on Kodiak Sciences (KOD)

For more information about research offerings from Zacks Investment Research, visit Zacks.com

Receive News & Ratings for Kodiak Sciences Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Kodiak Sciences and related companies with MarketBeat.com's FREE daily email newsletter.